US biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Monday that it has completed the transfer of the Investigational New Drug application (IND) for its breast cancer vaccine from Cleveland Clinic.
Anixa is now the trial sponsor for future development of the vaccine.
The company said that, with enrolment completed and encouraging immune response and safety data observed in the Phase 1 trial, it intends to advance the vaccine into a Phase 2 clinical trial and has assumed full sponsorship of the IND. Anixa is planning to use multiple clinical sites, including Cleveland Clinic, for the Phase 2 and other clinical trials.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA